| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Molekularpharmakologie, Medizinische Hochschule Hannover, Hannover, Germany;
DG Rheumatology, Hoechst Marion Roussel, Wiesbaden, Germany; and
Dompé Research Center, Via Campo di Pile, I-67100, L’Aquila, Italy
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
IL-1 effects are mediated by specific plasma membrane receptors. Two
closely related types of receptors for IL-1 have been cloned (4, 5), of
which type I IL-1 receptor (IL-1RI) transduces signals into the target
cell (6), whereas the function of a ligand sink or decoy receptor was
ascribed to type II IL-1 receptor (IL-1RII) (7). IL-1RI binds IL-1
or IL-1ß through its extracellular domain and then interacts with the
IL-1 receptor accessory protein (IL-1RAcP) (8) to form a functional
signaling receptor complex (9, 10). On the other hand, binding of
IL-1Ra to IL-1RI does not recruit IL-1RAcP, thus preventing formation
of the signaling complex (8). The ligand-induced association of the two
transmembrane molecules allows the interaction of the cytoplasmic
portions of receptor and coreceptor necessary for the association of
the adapter protein MyD 88 and the activation of the IL-1 receptor
associated protein kinases (IRAK) (11), which subsequently leads to the
activation of the transcription factor NF-
B (12, 13). Recently, a
second member of the IRAK family, termed IRAK-2, was cloned that is
able to interact with MyD 88 and the IL-1RI chain upon overexpression
in manner comparable to IRAK (14). As the extracellular domains which
bind the ligands IL-1, IL-1ß, or IL-1Ra are rather homologous in
IL-1RI and IL-1RII, it was tempting to speculate that, upon IL-1
binding, IL-1RII would also interact with IL-1RAcP.
Here we show that a chimeric receptor consisting of the extracellular and transmembrane portion of human IL-1RII (hIL-1RII) plus the signaling cytoplasmic tail of IL-1RI (15) can only signal in the precence of IL-1RAcP. Furthermore, we demonstrate the direct interaction of hIL-1RII with murine IL-1RAcP (mIL-1RAcP) by crosslinking and immunoprecipitation studies. These results prove the physical interaction of ligand-bound IL-1RII with IL-1RAcP. The fact that IL-1RAcP can interact with both types of ligated IL-1 receptors allows to propose the novel mechanism of coreceptor competition and suggests that down-regulation of IL-1 responsiveness is possible through sequestration of IL-1RAcP by IL-1RII.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mammalian cell culture was conducted at 37°C, 5% CO2. Murine EL-4 cells were maintained in RPMI 1640 supplemented with 5% (v/v) FCS, 1 mM pyruvate, nonessential amino acids (MEM), and 2 mM L-glutamine. Media were from BioWhittaker (Boehringer Ingelheim Bioproducts, Heidelberg, Germany) and supplements from Life Technologies (Eggenstein, Germany). EL-4 D6/76 cells (16) were a kind gift of W. Falk (Regensburg, Germany). EL-4 AcP1 is a clone derived from EL-4 D6/76, which overexpresses murine IL-1RAcP as described previously (10).
Plasmids and generation of stable cell lines and transient transfections
The expression plasmid pSVT7, encoding the IL-1R chimera (amino acids 1–369 of hIL-1RII and amino acids 340–552 of hIL-1RI; 15 was a kind gift of G. Macchia (L’Aquila, Italy). The expression plasmid pMM38 encoding full-length cDNA for hIL-1RII has also been described (17). A complete cDNA for murine IL-1RAcP was generated from the vector pEF-AcP (10) by PCR cloning and inserted into the KpnI/NotI sites of the expression vector pFLAG-CMV-1 (Kodak, New Haven, CT). The plasmid pBape Puro (18) encoded a puromycin resistance gene was kindly provided by B. Lüscher (Hannover, Germany).
To generate stable cell lines expressing the chimeric IL-1R EL-4 AcP1 cells (AcP1) or EL-4 D6/76 cells were cotransfected with pSVT7 and pBape Puro by electroporation as described previously (10). Transfected cells were maintained in medium containing penicillin/streptomycin and 2 µg/ml puromycin (Sigma, Deisenhofen, Germany) for 2 wk. Single cell clones were isolated from puromycin-resistant pools by limiting dilution (0.3 cell/well) and screened for expression of chimera mRNA using RT-PCR. From 13 AcP1-derived clones 1 expressed mRNA for the chimera, and from 58 EL-4 D6/76-derived clones 3 expressed mRNA for the chimera.
Transient transfection of EL-4 D6/76 cells was performed using DEAE-dextran as described (19) with minor modifications. In summary, cells were cultured overnight at a density of 2 x 105 cells/ml. Before transfection cells were washed twice with PBS and once with TBS (25 mM Tris-HCl (pH 7.4), 137 mM NaCl, 5 mM KCl, 0.6 mM Na2HPO4, 0.7 mM CaCl2, 0.5 mM MgCl2). Cells (5 x 106) were resuspended in a transfection solution containing a total of 0.5 µg DNA, 250 µg/ml DEAE-dextran (Pharmacia, Freiburg, Germany), and 40 µg/ml Chloroquine (Sigma) in TBS. Equal amounts of DNA were guaranteed by adding pcDNA3 or pFLAG-CMV-1, respectively. Transfection was conducted for 30 min at room temperature. After incubation cells were washed twice with medium and cultured for 18–24 h in 6-well plates.
Induction and quantitation of IL-2 production.
Cells were seeded at a density of 5 x 104
cells/well in microtiter plates with medium containing the calcium
ionophore A23187 (Sigma, 2.5 x 10-7 M) and different
concentrations of IL-1 (kind gift of J. Sims, Immunex, Seattle),
blocking anti-murine IL-1RI mAb (35F5, PharMingen, Hamburg,
Germany), blocking anti-human IL-1RII mAb (Genzyme, Cambridge, MA),
and an IL-1Ra mutein (DoB 0039 D; 20 as indicated in the figures.
After 18 h, supernatants were removed and IL-2 was measured using
the DuoSet for mouse IL-2 according to the manufacturer’s instructions
(Genzyme).
Crosslinking of IL-1R components
To investigate the physical interaction of IL-1RII with
IL-1RAcP, EL-4 D6/76 cells were transfected with various combinations
of expression plasmids as indicated in the figures. Radiolabeled
[125I]IL-1 was prepared by a standard chloramine-T
method. Transfected cells (2 x 107) were incubated
with 10–20 ng/ml [125I]IL-1 for 3 h. For
blocking of endogenous IL-1RI, 2 µg/ml of the mAb 35F5 (PharMingen)
were added in some experiments. Cells were washed twice with PBS and
resuspended in 5 mM Bis(sulfosuccinimidyl)suberate in PBS (Pierce,
Rockford, IL). After an additional hour the crosslinker was removed and
cells were solubilized for 20 min in 300 µl lysis buffer (20 mM Tris
(pH 7.4), 1 mM EGTA, 1 mM EDTA, 2 mM DTT, 0.5% Triton X-100). Nuclei
and cellular debris were removed by centrifugation at 13,000 x
g for 30 min. All steps were performed at 4°C. Lysates
were either used for further immunoprecipitations or prepared for
SDS-PAGE by heating with 50 µl of Laemmli buffer. Proteins were
separated by SDS-PAGE (7.5%) according to Laemmli (21) and visualized
by phosphoimaging (model G-250; Bio-Rad, München, Germany).
Immunoprecipitations
Murine IL-1RI was precipitated from the lysates using the nonblocking mAb 12A6 (PharMingen) at a concentration of 2 µg/500 µl lysates from 2 x 107 cells. Binding of the mAb was overnight at 4°C before 50 µl of a protein G-Sepharose slurry (Pharmacia) were added for further 4 h. Immunoprecipitates were washed twice with lysis buffer and then prepared for SDS-PAGE by heating with 50 µl of Laemmli buffer.
FLAG-tagged IL-1RAcP was precipitated from lysates with 25 µl of anti-FLAG-M2 affinity gel (Kodak, New Haven, CT) overnight. Immunoprecipitates were washed four times with a high salt buffer (1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 0.25 M NaCl, 0.01 M sodium phosphate (pH 7.0), 2 mM EDTA). FLAG-IL-1RAcP was released from the M2 Ab by adding an excess of FLAG peptide (100 µg/ml; Kodak) for 30 min. For precipitation of the hIL-1RII, these supernatants or lysates were incubated with 5 µg of a nonblocking anti hIL-1RII mAb (R.K., unpublished data) for 2 h at 4°C. Then 10 µg per 500 µl/sample of a goat anti-mouse Ig Fc Ab (Dianova, Hamburg, Germany) were added and incubated overnight. The immune complexes were precipitated with 50 µl of a protein G-Sepharose slurry (Pharmacia). Precipitates were washed four times with high salt buffer and analyzed as described above. Isotype control of the second immunoprecipitation was performed with the mouse IgG2a mAb OKT3.
Detection of IL-1RII/IL-1RAcP complexes in human B cells/monocytes
Human B cells and monocytes were prepared from buffy coats
obtained from the blood bank of the Medical School by a standard
protocol. Erythrocytes and neutrophils were removed by a Ficoll
separation. T cells were depleted by rosetting with erythrocytes from
sheep, and the remaining cells, mainly B cells and monocytes, were
cultured overnight in RPMI 1640 + 5% FCS. Nonadherent cells were
removed and washed twice with PBS. Binding and crosslinking of
[125I]IL-1 were performed as described for EL-4 cells.
For immunoprecipitation of hIL-1RAcP a rabbit antiserum was used (kindly provided by Dr. Z. Cao, Tularik, South San Francisco). Lysates and immunoprecipitates were analyzed as described above.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
However, a chimeric receptor consisting of the complete IL-1RII plus the cytoplasmic part of IL-1RI is capable of signaling as shown by Heguy et al. (15). We used this chimeric receptor to generate a cell system in which signal transduction transmitted via IL-1RII could be measured.
Generation of permanent EL-4 clones expressing the chimeric IL-1R
The murine cell line EL4 D6/76 expresses about 2000 IL-1RI per cell but does not respond to IL-1 because it does not express IL-1RAcP. Transfection with IL-1RAcP reconstituted IL-1 responsiveness completely (9, 10), demonstrating that IL-1RI requires IL-1RAcP to transduce signals. To test whether the chimeric receptor would also need IL-1RAcP for signal transduction, we transfected EL-4 D6/76 with this construct. In parallel, we transfected the clone AcP1 which was derived from EL-4 D6/76 and overexpresses IL-1RAcP (10) with the chimeric receptor, so the resulting transfectants only differed in IL-1RAcP expression. Permanent clones were established from both pools. The expression of mRNA for the chimeric receptor and IL-1RAcP was ascertained by RT-PCR analysis (data not shown). The IL-1RAcP negative clone was termed D-Chim, the IL-RAcP positive clone Chim9.
The chimeric IL-1R signals only in the presence of IL-1RAcP
IL-1 induces IL-2 synthesis in EL-4 cells (22). Expression of the
chimeric receptor in the absence of IL-1RAcP by itself did not confer
IL-1 responsiveness. Thus, D-Chim cells did not respond to IL-1 (Fig. 1
A). In AcP1 cells and Chim9
cells IL-1 induced IL-2 production (Fig. 1A). As Chim9 cells
express both the endogenous murine IL-1RI and the chimeric receptor, we
had to demonstrate the contribution of the chimeric receptor to IL-1
signaling. Therefore, the endogenous mIL-1RI were blocked by increasing
concentrations of the anti-mIL-1RI mAb 35F5, and the cells were
stimulated with a constant concentration of 100 pg/ml of IL-1.
Complete inhibition of IL-1 induced IL-2 synthesis was achieved in AcP1
cells that only posses mIL-1RI (Fig. 1A), whereas in Chim9
cells only a partial neutralization was observed even at high
concentrations of blocking Ab. IL-1-mediated IL-2 production in Chim9
cells was completely inhibited by adding a blocking anti-hIL-1RII
mAb to the system in which mIL-1RI had already been blocked by 100
ng/ml 35F5 (Fig. 1B), indicating that the residual IL-1
effect was mediated by the chimeric receptor. This effect was
concentration dependent and specific for this neutralizing Ab as
isotype matched control Abs did not influence IL-1 induced IL-2 release
(data not shown).
|
). In Chim9 cells, which express the
chimeric receptor with the hIL-1RII binding site in addition to
endogenous mIL-1RI, about 100-fold higher concentration of IL-1Ra was
required to achieve a comparable degree of inhibition. This is in good
accord with the published differences in affinities of IL-1Ra for
IL-1RI and IL-1RII, respectively (23) and reflects the contribution of
the chimeric receptor to IL-1 signaling in Chim9 cells.
|
To demonstrate direct protein-protein interaction of IL-1RII with
IL-1RAcP, we cotransfected these molecules transiently into EL-4 D6/76
cells that express endogenous mIL-1RI, but not IL-1RII or IL-1RAcP. The
transfectants were incubated with [125I]IL-1, and
surface molecules were crosslinked with the homobifunctional
crosslinker BS3. Immunoprecipitates of mIL-1RI from
mock-transfected EL-4 D6/76 cells showed a band at about 100 kDa which
corresponds to the 80-kDa mIL-1RI with the 17-kDa
[125I]IL-1 covalently crosslinked to it (Fig. 3A, lane 1). When
EL-4 D6/76 cells were transfected with IL-1RAcP, an additional complex
of 180–200 kDa was immunoprecipitated that consists of mIL-1RI plus
[125I]IL-1 and IL-1RacP (Fig. 3A,
lane 2). Due to the inefficient crosslinking reaction
[125I]IL-1 is partially liberated from the
noncovalently associated complexes after heating the samples to 95°C.
Therefore, free [125I]IL-1 is detected migrating at 17
kDa.
|
to the cells. Under these conditions
no signal can be seen in EL-4 D6/76 cells, because no IL-1 binding
sites are available (Fig. 3
B, lane 3). The same
is true for cells only transfected with IL-1RAcP (Fig. 3B,
lane 5) supporting the findings of Greenfeder et al. (8)
that IL-1RAcP does not bind IL-1 itself. Cells transfected with
hIL-1RII showed a faint band at about 80 kDa (Fig. 3B,
lane 4). An additional band in the high m.w. range was
always visible. Both complexes could be immunoprecipitated with an anti
hIL-1RII mAb (data not shown), suggesting that they consist of
[125I]IL-1 crosslinked to IL-1RII. This high m.w.
complex may be a dimer of human IL-1RII, because such a comparable band
was also observed in the human B-cell line RAJI, which expresses
hIL-1RII but not IL-1RAcP or IL-1RI (D.L. and M.U.M., unpublished
results). In EL-4 D6/76 cells cotransfected with hIL-1RII and
mIL-1RAcP, a marked complex of 180–200 kDa was observed (Fig. 3B, lane 6). This high m.w. complex was
absent when cells were incubated with radiolabeled IL-1Ra (data not
shown). Identification of IL-1RAcP and IL-1RII in the high m.w. complex by sequential immunoprecipitation
The presence of hIL-1RII and IL-1RAcP in the high m.w. complex was
demonstrated by performing sequential immunoprecipitations from lysates
of EL-4 D6/76 cells cotransfected with hIL-1RII and FLAG-epitope-tagged
mIL-1RAcP. Again, endogenous mIL-1RI were blocked with mAb 35F5 before
[125I]IL-1 was added and crosslinking performed.
Complexes containing FLAG-tagged mIL-1RAcP were precipitated from
lysates with the anti-FLAG mAb M2 bound to agarose beads.
Precipitates were stringently washed with a high salt buffer. Analysis
of this first immunoprecipitation showed three bands: free,
[125I]IL-1 at 17 kDa; ligated hIL-1RII at 80 kDa; and
the high m.w. complex at about 180–200 kDa (Fig. 4A, lanes 4 and
5, which are identical). The complexes bound via the
FLAG-tag on IL-1RAcP were released by adding an excess of FLAG-peptide,
and a second immunoprecipitation step was performed with a nonblocking
anti-hIL-1RII mAb. Analysis of this immunoprecipitate yielded three
bands (Fig. 4B, lane 4), free
[125I]IL-1, ligated IL-1RII at 80 kDa, and the high
m.w. complex at 180–200 kDa. In parallel a sample was incubated with
an isotype-matched irrelevant Ab and treated identically. None of the
complexes could be immunoprecipitated with this control Ab,
demonstrating the specificity of this immunorpecipitation step (Fig. 4B, lane 5). These results demonstrate that the
high m.w. complex contains IL-1RII and IL-1RAcP, both crosslinked to
[125I]IL-1.
|
Crosslinking experiments were performed with normal human B cells
in the presence of radiolabeled IL-1. Three bands were observed in
lysates from these B cells. Free [125I]IL-1 at 17 kDa,
ligated hIL-1RII at 80 kDa, and a high m.w. complex of 180–200 kDa
(Fig. 5, lane 1). A specific
antiserum against hIL-1RAcP precipitated this high m.w. complex besides
of the 82-kDa band (Fig. 5, lane 2), while a rabbit
pre-immune serum yielded no bands (Fig. 5, lane 3). The
residual lysate was specifically depleted of the high m.w. band (Fig. 5, lane 4) after immunoprecipiation of hIL-1RAcP. The same
pattern was observed in B cells from four other donors (data not
shown). These results show that the formation of a trimeric complex
consisting of IL-1 bound to IL-1RII and IL-1RAcP is possible in normal
human B cells.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
By employing chimeric receptors encompassing the extracellular and transmembrane portion of IL-1RII and the cytoplasmic domain of IL-1RI, we demonstrated that such an interaction takes place. Expression of chimeric receptors alone did not confer IL-1 responsiveness to cells lacking IL-1RAcP: Both endogenous mIL-1RI and chimeric hIL-1R required IL-1RAcP to form a signaling complex. We demonstrated that both the natural and the chimeric receptor contributed to the IL-1 response in our cloned cells by sequentially blocking endogenous mIL-1RI and then hIL-1RII binding sites with neutralizing Abs. A result that was further substantiated by the observation that IL-1Ra was less potent in inhibiting IL-1-induced IL-2 release in cells expressing chimeric receptors in addition to the endogenous mIL-1RI. In our clone a 100-fold more IL-1Ra was required to achieve inhibition of the response mediated by chimeric receptors, which is in good accordance to the published difference in affinities of IL-1Ra for the two types of IL-1Rs (23).
Thus, as far as extracellular interaction with IL-1RAcP is concerned, chimeric receptor and IL-1RI behave identically. It can be assumed that heterodimerization is mediated by the extracellular recognition of the ligated receptors by IL-1RAcP. Indeed, recently Huang et al. (24) showed that the cytoplasmic tails are not required for IL-1-mediated interaction of the extracellular domains of IL-1RI and IL-1RAcP.
Initiation of signal transduction by IL-1, however, quite clearly requires the cytoplasmic part of IL-1RI (25, 26, 27) and very recent results suggest that also the cytoplasmic part of IL-1RAcP is indispensible for efficient signaling to occur (11, 12, 24, 28). Thus, one could argue that the cytoplasmic tails of IL-1RI and IL-1RAcP may contribute to the formation of the heterotrimeric complexes, an interaction which would be possible in IL-1RI and the chimeric receptor but obviously not in the natural IL-1RII.
We showed the direct protein-protein interaction of normal human IL-1RII with IL-1RAcP by crosslinking these two molecules in the presence of radiolabeled IL-1. A high m.w. complex was identified which consisted of IL-1 bound to hIL-1RII and the coreceptor molecule as demonstrated by consecutive immunoprecipitations with the respective Abs. This result shows that the cytoplasmic tail of the chimeric receptor is not required for ligand mediated association in our clones. Comparison of the heterotrimeric complex containing either hIL-1RII or mIL-1RI showed no detectable difference in the apparent m.w. determined in the gels, although the two ligated receptor types showed a clear difference of 15–17 kDa. This may be due to sterical effects in the crosslinked components affecting the electrophoretic mobility. In addition, the band of the high m.w. complex was relatively diffuse, probably due to the fact that IL-1Rs and IL-1RAcP are heavily glycosylated. The size of the heterotrimeric complexes we observed in our transfected cells is in good accordance with the complex of IL-1RI plus IL-1 and IL-1RAcP reported by Greenfeder et al. (8).
Finally, we investigated whether such a heterotrimeric complex of hIL-1RII plus IL-1 and hIL-1RAcP could be visualized in normal cells. And indeed, we were able to demonstrate a high m.w. complex in normal human B cells that predominantly express IL-1RII (reviewed in refs. 1 and 5). hIL-1RAcP was identified as component of this high m.w. complex in human B cells by immunoprecipitation with a specific antiserum.
In summary, the data presented here show that IL-1RII and IL-1RAcP can
interact in the presence of IL-1. This may have important biological
consequences. We propose that this interaction will result in a
competition of IL-1Rs for the coreceptor. And as IL-1RAcP is
indispensible for signaling via IL-1RI, the interaction with IL-1RII
should have an effect on IL-1 responsiveness. Indeed, if IL-1RII is
expressed at a much higher frequency than IL-1RI this leads to a
decrease in sensitivity to IL-1 as observed in fibroblasts (17) and
keratinocytes transfected with hIL-1RII (29). This result was explained
by the authors as capture and sequestration of ligand by IL-1RII, the
so called ligand sink effect. In addition to this effect, we propose a
novel regulatory role for IL-1RII based on the observation that
ligand-bound IL-1RII can sequester IL-1RAcP into a nonfunctional
complex. IL-1RII can compete for the coreceptor and distract IL-1RAcP
from the signaling complex with IL-1RI. A model of this coreceptor
competition is depicted in Fig. 6. In
this model the ratio of IL-1RI to IL-1RII defines the threshold at
which a given cell can respond to IL-1, if the availability of IL-1RAcP
is limited. In this view, regulation of surface expression of IL-1RAcP
becomes of pivotal importance in determining responsiveness to IL-1.
Presently, little data are available, and they show that only few
accessory molecules are expressed per cell (International Patent
Application Number WO 96/23067 by F.Hoffmann-La Roche AG, Basle,
Switzerland). In addition, IL-1RAcP does not seem to be significantly
regulated at the mRNA level (D.L. and M.U.M., unpublished data) while
surface expression of IL-1RII is tightly regulated. On one hand
anti-inflammatory cytokines and drugs, such as IL-4 and
glucocorticoids, can up-regulate IL-1RII by stimulating de novo
synthesis (7). On the other hand, IL-1RII can be shedded from the
surface rapidly by proteolytic cleavage (30), a process which is highly
regulated by TNF and IL-8 (31).
|
Note.
While this manuscript was in review, Malinowsky et al. (32) reported on the interaction of IL-1RAcP with IL-1RII in transfected HEK-293 cells using rhIL-1ß.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Current address: Tularik Inc., Two Corporate Drive, South San Francisco, CA 94080.
3 Address correspondence and reprint requests to Dr. Michael U. Martin, Medizinische Hochschule Hannover, Institut für Molekularpharmakologie OE 5320, D-30623 Hannover, Germany. E-mail address:
4 Abbreviations used in this paper: IL-1Ra, IL-1 receptor antagonist; IL-1RI, type I IL-1 receptor; IL-1RII, type II IL-1 receptor; IL-1RAcP, IL-1 receptor accessory protein; IRAK, IL-1 receptor-associated protein kinase; h, human; m, murine.
Received for publication April 2, 1998. Accepted for publication August 12, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity. J. Biol. Chem. 270:16514.B signal transduction. J. Biol. Chem. 269:1579.This article has been cited by other articles:
|
|
 |
|
  S. Ali, M. Huber, C. Kollewe, S. C. Bischoff, W. Falk, and M. U. Martin IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells PNAS, November 20, 2007; 104(47): 18660 - 18665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Gomes, G. H. Esteves, A. F. Carvalho, E. B. Cristo, R. Hirata Jr., W. K. Martins, S. M. Marques, L. P. Camargo, H. Brentani, A. Pelosof, et al. Expression Profile of Malignant and Nonmalignant Lesions of Esophagus and Stomach: Differential Activity of Functional Modules Related to Inflammation and Lipid Metabolism Cancer Res., August 15, 2005; 65(16): 7127 - 7136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Jensen and A. S. Whitehead The 3' Untranslated Region of the Membrane-Bound IL-1R Accessory Protein mRNA Confers Tissue-Specific Destabilization J. Immunol., November 15, 2004; 173(10): 6248 - 6258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Levine Mechanisms of Soluble Cytokine Receptor Generation J. Immunol., November 1, 2004; 173(9): 5343 - 5348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mantovani, M. Locati, N. Polentarutti, A. Vecchi, and C. Garlanda Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR J. Leukoc. Biol., May 1, 2004; 75(5): 738 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, F. N. Rouhani, F. Hawari, and S. J. Levine Shedding of the Type II IL-1 Decoy Receptor Requires a Multifunctional Aminopeptidase, Aminopeptidase Regulator of TNF Receptor Type 1 Shedding J. Immunol., December 15, 2003; 171(12): 6814 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bourke, A. Cassetti, A. Villa, E. Fadlon, F. Colotta, and A. Mantovani IL-1{beta} Scavenging by the Type II IL-1 Decoy Receptor in Human Neutrophils J. Immunol., June 15, 2003; 170(12): 5999 - 6005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bufler, T. Azam, F. Gamboni-Robertson, L. L. Reznikov, S. Kumar, C. A. Dinarello, and S.-H. Kim A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity PNAS, October 15, 2002; 99(21): 13723 - 13728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Muller, G. Peri, A. Doni, A. P. Perruchoud, R. Landmann, F. Pasqualini, and A. Mantovani High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration J. Leukoc. Biol., October 1, 2002; 72(4): 643 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Attur, M. N. Dave, M. Y. Leung, C. Cipolletta, M. Meseck, S. L. C. Woo, and A. R. Amin Functional Genomic Analysis of Type II IL-1{beta} Decoy Receptor: Potential for Gene Therapy in Human Arthritis and Inflammation J. Immunol., February 15, 2002; 168(4): 2001 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Debets, J. C. Timans, B. Homey, S. Zurawski, T. R. Sana, S. Lo, J. Wagner, G. Edwards, T. Clifford, S. Menon, et al. Two Novel IL-1 Family Members, IL-1{delta} and IL-1{epsilon}, Function as an Antagonist and Agonist of NF-{kappa}B Activation Through the Orphan IL-1 Receptor-Related Protein 2 J. Immunol., August 1, 2001; 167(3): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Cubitt, R. N. Lausch, and J. E. Oakes Synthesis of Type II Interleukin-1 Receptors by Human Corneal Epithelial Cells but not by Keratocytes Invest. Ophthalmol. Vis. Sci., March 1, 2001; 42(3): 701 - 704. [Abstract] [Full Text]
|
|
|
|
|
|
R. Debets, J. C. Timans, T. Churakowa, S. Zurawski, R. de Waal Malefyt, K. W. Moore, J. S. Abrams, A. O'Garra, J. F. Bazan, and R. A. Kastelein IL-18 Receptors, Their Role in Ligand Binding and Function: Anti-IL-1RAcPL Antibody, a Potent Antagonist of IL-18 J. Immunol., November 1, 2000; 165(9): 4950 - 4956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Neumann, C. Kollewe, M. U. Martin, and D. Boraschi The Membrane Form of the Type II IL-1 Receptor Accounts for Inhibitory Function J. Immunol., September 15, 2000; 165(6): 3350 - 3357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. J. O'Neill The Interleukin-1 Receptor/Toll-like Receptor Superfamily: Signal Transduction During Inflammation and Host Defense Sci. Signal., August 8, 2000; 2000(44): re1 - re1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Jensen, M. Muzio, A. Mantovani, and A. S. Whitehead IL-1 Signaling Cascade in Liver Cells and the Involvement of a Soluble Form of the IL-1 Receptor Accessory Protein ,2 J. Immunol., May 15, 2000; 164(10): 5277 - 5286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Penton-Rol, S. Orlando, N. Polentarutti, S. Bernasconi, M. Muzio, M. Introna, and A. Mantovani Bacterial Lipopolysaccharide Causes Rapid Shedding, Followed by Inhibition of mRNA Expression, of the IL-1 Type II Receptor, with Concomitant Up-Regulation of the Type I Receptor and Induction of Incompletely Spliced Transcripts J. Immunol., March 1, 1999; 162(5): 2931 - 2938. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
, IL-1RAcP
pos., IL-1RII/IL-1RI pos.), and D-Chim cells (
, IL-1RAcP neg.,
IL-1RII/IL-1RI pos.) were treated with 50 pg/ml rhIL-1
)
or in the presence (
